Intrinsic Therapeutics Receives PMA for Barricaid Annular Closure Device

Intrinsic Therapeutics gained FDA Premarket Approval (PMA) for the Barricaid annular closure device for partial annulus replacement to treat herniated discs.

In late 2017, FDA's Orthopaedic and Rehabilitation Devices Panel had recommended against approval of Barricaid, voting 9 to 5 that it is safe, 12 to 1 (with 1 abstaining) that it is...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us